Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. The company is headquartered in San Diego, California and currently employs 2,600 full-time employees. The company went IPO on 2013-11-13. The firm is focused on the design, development, and commercialization of technology solutions for people living with diabetes. The company manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. Its manufacturing, sales, and support activities principally focus on its flagship pump platform, the t:slim X2, and its complementary product offerings. Its t:slim X2 is based on the Company's technology platform and is the smallest durable insulin pump available in the United States. The firm has commercially offered two different automated insulin dosing (AID) algorithms on t:slim X2, including Control-IQ technology, which is an advanced hybrid-closed loop feature, designed to help increase a user's time in their targeted glycemic range. The company was cleared by the Food and Drug Administration (FDA) to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar.